JSPR, US4718712023

Jasper Therapeutics stock falls 5.48 percent as CFO exit nears

Published on 10/04/2026 at 09:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jasper Therapeutics stock faced a CFO transition on September 23, 2026, while H.C. Wainwright kept a USD 20.00 target. Second-quarter GAAP loss narrowed to USD 2.76 million.

JSPR, US4718712023, Illustration mit AI erstellt.

Jasper Therapeutics stock (ISIN US4718712023) fell 5.48 percent to USD 0.57 on Nasdaq on October 2, 2026, as the biotechnology company approached a senior finance transition. The move followed a September 23, 2026 resignation notice that puts Chief Financial Officer Herb Cross's departure on the calendar for October 9.

CFO transition sets the near term

According to StockTitan, Jasper appointed Chief Executive Officer Jeet Mahal as interim principal financial officer, Rick Ruiz as interim principal accounting officer and Matthew Ros as interim corporate secretary. Ruiz will retain a USD 364,000 annual base salary, while the appointments take effect when Cross leaves.

The personnel change matters because Jasper remains a clinical-stage company with several development programs and a small cash base. The investor-relations page describes KP-104, briquilimab and KP-701 as pipeline assets spanning immune-mediated disease, nephrology and stem-cell-related indications, according to Jasper Therapeutics.

Loss narrows in Q2 2026

For the quarter ended June 30, 2026, Jasper reported a GAAP net loss of USD 2.76 million, down from USD 26.72 million in the comparable quarter of 2025, according to Markets Insider. Finance data also show a diluted loss of USD 0.10 per share in Q2 2026, compared with USD 0.04 in Q1 2026, while operating cash flow was negative USD 6.919 million for the quarter.

As of June 30, 2026, cash and cash equivalents stood at USD 7.3 million. The company's next development milestones include regulatory discussions for KP-104 and briquilimab, with further program steps expected in 2027, according to RTTNews.

Analyst target remains far higher

H.C. Wainwright maintained a Buy rating and a USD 20.00 price target in a September 21, 2026 update carried by Markets Insider. Against the October 2 price of USD 0.57, that target lies 3,408.8 percent above the share price, making clinical execution and financing capacity the central valuation variables.

Jasper stock stays near its yearly low

Jasper Therapeutics was last at USD 0.57 on Nasdaq on October 2, 2026 at 4:00 p.m. ET. The session covered USD 0.56 to USD 0.61, volume was 234,384 shares, and the 52-week range was USD 0.32 to USD 2.69; the next earnings date is November 5, 2026, according to Investing.com.